SPSiba Prosad Paul

Siba Prosad Paul

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Siba Prosad Paul has a total of 250 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • NICE guideline review: Epilepsies in children, young people and adults NG217

    by Katherine Elizabeth Anne Jones, Rachel Howells, Andrew A Mallick, Siba Prosad Paul, Indranil Dey

    In April 2022, NICE published updated guidelines for the diagnosis and management of epilepsies in children, young people and adults (NG217), aiming to improve diagnosis and treatment and reduce the risks for people with epilepsy. The recommendations reflect updated evidence about the medical management of different seizure types as well as more detailed guidance on referral, investigation, diagnosis and liaison with tertiary services. It replaces CG137, published in January 2012.


  • Open Access

    Turnaround times for molecular testing of pediatric viral cerebrospinal fluid samples in United Kingdom laboratories

    by Siba Prosad Paul, Varathagini Balakumar, Arangan Kirubakaran, Jothilingam Niharika, Paul Anthony Heaton, Paul Christopher Turner

    Rapid molecular testing has revolutionized the management of suspected viral meningitis and encephalitis by providing an etiological diagnosis in < 90 min with potential to improve outcomes and shorten inpatient stays. However, use of molecular assays can vary widely. To evaluate current practice for molecular testing of pediatric cerebrospinal fluid (CSF) samples across the United Kingdom using a structured questionnaire. A structured telephone questionnaire survey was conducted between July and August 2020. Data was collected on the availability of viral CSF nucleic acid amplification testing (NAAT), criteria used for testing and turnaround times including the impact of the coronavirus disease 2019 pandemic. Of 196/212 (92%) microbiology laboratories responded; 63/196 (32%) were excluded from final analysis as they had no on-site microbiology laboratory and outsourced their samples. Of 133 Laboratories included in the study, 47/133 (35%) had onsite facilities for viral CSF NAAT. Hospitals currently undertaking onsite NAAT (n = 47) had much faster turnaround times with 39 centers (83%) providing results in ≤ 24 h as compared to those referring samples to neighboring laboratories (5/86; 6%). Onsite/near-patient rapid NAAT (including polymerase chain reaction) is recommended wherever possible to optimize patient management in the acute setting.

  • Open Access

    Turnaround times for molecular testing of pediatric viral cerebrospinal fluid samples in United Kingdom laboratories

    by Siba Prosad Paul, Varathagini Balakumar, Arangan Kirubakaran, Jothilingam Niharika, Paul Anthony Heaton, Paul Christopher Turner

    Rapid molecular testing has revolutionized the management of suspected viral meningitis and encephalitis by providing an etiological diagnosis in < 90 min with potential to improve outcomes and shorten inpatient stays. However, use of molecular assays can vary widely. To evaluate current practice for molecular testing of pediatric cerebrospinal fluid (CSF) samples across the United Kingdom using a structured questionnaire. A structured telephone questionnaire survey was conducted between July and August 2020. Data was collected on the availability of viral CSF nucleic acid amplification testing (NAAT), criteria used for testing and turnaround times including the impact of the coronavirus disease 2019 pandemic. Of 196/212 (92%) microbiology laboratories responded; 63/196 (32%) were excluded from final analysis as they had no on-site microbiology laboratory and outsourced their samples. Of 133 Laboratories included in the study, 47/133 (35%) had onsite facilities for viral CSF NAAT. Hospitals currently undertaking onsite NAAT (n = 47) had much faster turnaround times with 39 centers (83%) providing results in ≤ 24 h as compared to those referring samples to neighboring laboratories (5/86; 6%). Onsite/near-patient rapid NAAT (including polymerase chain reaction) is recommended wherever possible to optimize patient management in the acute setting.

  • Chryseobacterium indologenes Bacteraemia: A Potential Cause of Early-onset Neonatal Sepsis in a Full-term Baby

    by Siba Prosad Paul, Paul Anthony Heaton

    Chryseobacterium indologenes is considered as an emerging pathogen known to cause pneumonia, bacteremia, and meningitis in children. It has been reported previously, mainly from the Indian subcontinent, as a rare cause of early-onset neonatal infection, mostly affecting preterm infants. We report the first case in the United Kingdom in which C. indologenes was isolated from the blood culture of a term infant who was clinically suspected of having early-onset neonatal sepsis. Our case had a good outcome, but mortality has been reported in published literature. A positive neonatal blood culture of C. indologenes should not automatically be considered as a contaminant; and a joint discussion between neonatologists and microbiologists should determine the appropriate management and antibiotic regimen.


  • Pancreatic Transection in a 6-year Child Following Bicycle Handlebar Injury

    by Geetanjali Sahariah Khound, Dibyajyoti Bora, Rekha Khaund Borkotoky, Siba Prosad Paul

    Bicycle handlebar injuries are the commonest cause of pancreatic trauma in children and adolescents, especially in males. Recognition of such injuries and initiation of correct treatment may be delayed when there is no abdominal wall bruising. We present a case of a 6-year boy with severe pancreatic trauma, who was referred from a local hospital following bicycle handlebar injury five days earlier. Contrast-enhanced computed tomography showed grade III pancreatic injury, which was repaired the following day; and he subsequently made a good recovery. The case highlights challenges faced by non-specialist clinicians working in resource-limited settings in diagnosing these injuries.


  • Painless expanding facial swelling

    by Paul Anthony Heaton, Krzysztof Piotr Zaborowski, Stephen David Holwill, Graham David Merrick, Siba Prosad Paul

    Case historyA previously healthy 11-year-old girl sustained a mosquito bite on her right cheek while on holiday in rural Bangladesh. A painless lump developed at the site, and over the ensuing 2 months gradually expanded. She was otherwise completely asymptomatic; there was no family history of note. On examination, there was obvious swelling affecting the right cheek and visible abnormality of the upper gum with displacement of the right upper central incisor (figure 1).edpract;archdischild-2020-320371v1/F1F1F1Figure 1Swelling of gum and displacement of tooth.The facial swelling measured 4×5 cm, was firm to touch, non-fluctuant, painless and non-tender; no other abnormalities were present. Blood results at presentation are shown in box 1.Box 1Blood results at presentationHaemoglobin 132 g/L (115-155).White cell count 6.92×109/L (5.0-13.0).Platelets 359×109/L.Erythrocyte sedimentation rate 7 mm/hour (0-12).C-reactive protein 2 mg/L (0-10).Calcium 2.32 mmol/L (2.1-2.6).Alkaline phosphatase 242 u/L (78-213).Lactate dehydrogenase 391 u/L (250-450).MRI scan (figure 2) showed well-defined unilocular hyperintense signal cystic lesion measuring 40×38×40 mm involving right-sided alveolar process of maxilla completely filling the right maxillary sinus.edpract;archdischild-2020-320371v1/F2F2F2Figure 2MRI showing right-sided cyst arising from maxilla. QUESTION 1: What is the most likely diagnosis?Burkitt's lymphomaEwing's sarcomaOdontogenic keratocystRhabdomyosarcomaMelioidosisSolitary cystic ameloblastoma QUESTION 2: What is the appropriate next step?Fine needle aspiration of cystExcision of lesionBone marrow aspirationMagnetic resonance imaging of thorax and abdomenStart intravenous ceftazidime Answers can be found on page XX .

  • Evidence supporting safe diagnosis of coeliac disease in children with antitissue transglutaminase titre ≥5 times upper limit of normal

    by Siba Prosad Paul, Daniyal Isam Raja, Bhupinder Kaur Sandhu, Srinivasa R Rao, Christine H Spray, Anthony Edward Wiskin, Lakshmipriya Selvarajan, Eleni Volonaki, Pramila Ramani, Lina Bourhan Tashtoush, et al.

    Objective European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) guidelines on coeliac disease (CD) recommend that children who have IgA-based antitissue transglutaminase (TGA-IgA) titre ≥10× upper limit of normal (ULN) and positive antiendomysial antibody, can be reliably diagnosed with CD via the no-biopsy pathway. The aim of this study was to examine the relationship between TGA-IgA ≥5×ULN and histologically confirmed diagnosis of CD. Methods Data including TGA-IgA levels at upper gastrointestinal endoscopy and histological findings from children diagnosed with CD following endoscopy from 2006 to 2021 were analysed. CD was confirmed by Marsh-Oberhuber histological grading 2 to 3 c. Statistical analysis was performed using χ² analysis (pResults 722 of 758 children had histological confirmation of CD. 457 children had TGA-IgA ≥5×ULN and 455 (99.5%) of these had histological confirmation for CD; the two that did not had eventual diagnosis of CD based on clinicopathological features. 114 of 457 had between TGA-IgA ≥5×ULN and Conclusion 99.5% of children with TGA-IgA ≥5×ULN had histological confirmation of CD, suggesting that CD diagnosis can be made securely in children with TGA-IgA ≥5×ULN. If other studies confirm this finding, there is a case to be made to modify the ESPGHAN guidelines to a lower threshold of TGA-IgA for serological diagnosis of CD.


  • Key messages from a guideline: RCEM best practice guideline—ingestion of super-strong magnets in children

    by Vamsi Krishna Gangalam, Siba Prosad Paul

    Reasons identified were: unwitnessed ingestion, adopting a ‘watch and wait’ approach considered appropriate for other swallowed items, reluctance for lateral X-ray projections and abdominal X-ray (AXR) by radiology teams, and delay in surgical review/intervention.1 2


  • Abdominal X-rays in children: indications, procedure and interpretation

    by Siba Prosad Paul, Florence Holbrook, Lisa Plowman, Julia James

    Abdominal X-rays (AXRs) are often used as an imaging modality in children who present with abdominal pain with a suspected serious underlying pathology. Nausea, vomiting and constipation that are unresponsive to treatment may also prompt a request for an AXR in a child. Nurses play an important role in ensuring that requests for AXRs in children are appropriate and that the procedure is performed safely. This is the second of two articles on the use of AXRs for diagnosing abdominal pathologies in childhood. The first article focused on AXRs in neonates. This one focuses on AXRs in children, discussing their indications, procedure and interpretation and describing abdominal conditions in children for which an AXR is likely to support diagnosis.